8-K
filed September 17, 2021, 7:59 PM ET
ticker ENVB
CIK 0000890821
M&A
confidence high
sentiment positive
materiality 0.75
Enveric completes MagicMed acquisition; issues 9.95M shares (~31.7% ownership)
Enveric Biosciences, Inc.
- Enveric issued 9,951,237 shares to MagicMed shareholders, representing ~31.7% of combined company.
- Enveric received ~$4 million CAD cash from MagicMed treasury at closing.
- Dr. Joseph Tucker (ex-MagicMed CEO) appointed CEO of Enveric; David Johnson becomes Executive Chairman.
- Dr. Peter Facchini appointed Chief Scientific Officer; Dr. Jillian Hagel appointed Chief Technology Officer.
- Board expanded from 5 to 7; Tucker and Brad Thompson joined as directors.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Dr. Jillian Hagel was appointed as Chief Technology Officer at Enveric Biosciences, Inc..
- Action
- appointed
- Role
- Chief Technology Officer
Exact text from the filing
the Company appointed each of (i) Dr. Tucker, 53, (ii) Dr. Peter Facchini, 58 and (iii) Dr. Jillian Hagel, 43, to be Chief Executive Officer, Chief Scientific Officer and Chief Technology Officer, respectively
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Dr. Joseph Tucker was appointed as Director at Enveric Biosciences, Inc..
- Action
- appointed
- Role
- Director
Exact text from the filing
the Company appointed each of (i) Dr. Joseph Tucker, who served as president and chief executive officer, and as a director, of MagicMed immediately prior to the Effective Time and (ii) Brad Thompson, who served as a director of MagicMed immediately prior to the Effective Time, to the Company’s board of directors
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
David Johnson changed role as Executive Chairman at Enveric Biosciences, Inc..
- Action
- assigned
- Role
- Executive Chairman
Exact text from the filing
assigned David Johnson, 63, the title of Executive Chairman of the Company, and removed the title of Chief Executive Officer.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Brad Thompson was appointed as Director at Enveric Biosciences, Inc..
- Action
- appointed
- Role
- Director
Exact text from the filing
the Company appointed each of (i) Dr. Joseph Tucker, who served as president and chief executive officer, and as a director, of MagicMed immediately prior to the Effective Time and (ii) Brad Thompson, who served as a director of MagicMed immediately prior to the Effective Time, to the Company’s board of directors
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Dr. Peter Facchini was appointed as Chief Scientific Officer at Enveric Biosciences, Inc..
- Action
- appointed
- Role
- Chief Scientific Officer
Exact text from the filing
the Company appointed each of (i) Dr. Tucker, 53, (ii) Dr. Peter Facchini, 58 and (iii) Dr. Jillian Hagel, 43, to be Chief Executive Officer, Chief Scientific Officer and Chief Technology Officer, respectively
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Dr. Joseph Tucker was appointed as Chief Executive Officer at Enveric Biosciences, Inc..
- Action
- appointed
- Role
- Chief Executive Officer
Exact text from the filing
the Company appointed each of (i) Dr. Tucker, 53, (ii) Dr. Peter Facchini, 58 and (iii) Dr. Jillian Hagel, 43, to be Chief Executive Officer, Chief Scientific Officer and Chief Technology Officer, respectively
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.